Plain-English translation of NCT07016412 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new inhaled medication called ensifentrine-glycopyrrolate, which combines two drugs to help open your airways and make breathing easier. The study will compare this two-drug combination at two different strengths against each drug used alone and against a placebo (a dummy treatment with no active medication). Researchers want to see which version works best for people with chronic obstructive pulmonary disease, commonly called COPD.
COPD makes it hard to breathe because the airways in your lungs become narrowed and blocked. While doctors have medications that can help, this trial is testing whether combining two drugs together in one inhaler works better than using them separately, which could make treatment simpler and more effective for patients.
You likely qualify if…
You likely don't qualify if…
You would participate for about 7 weeks total: roughly 1–2 weeks of screening visits with breathing tests and medical history review, 4 weeks of treatment where you inhale your assigned medication twice daily using a nebulizer machine, and a final 1-week follow-up visit. You'll be randomly assigned to one of six groups — either the two-drug combination at one of two doses, one of the individual drugs alone, or a placebo. Throughout the study, your doctors will monitor how well you're breathing and check for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States